Disease Diagnosis TRIZ Cases

Maternal salivary uric acid measurement identifies foetal distress with high sensitivity, reducing false positives from blood pressure and protein tests.

A host biomarker panel detects neural cell adhesion molecule and immune markers in blood samples to identify active tuberculosis infection.

GC/MS quantifies specific metabolites in urine to detect psychiatric disorders, replacing subjective clinical observation with objective analytical data.

Aptamer compositions detect Porphyromonas gingivalis and Prevotella pallens in oral samples using high-affinity oligonucleotide binding.

Functionalized inorganic nanoparticles mimic protein aggregates, resolving instability and limited adaptability of existing disease-specific standards.

Isotope-labeled surrogate peptides enable precise protein quantification for non-invasive diagnosis, replacing invasive colonoscopies.

Assessing EGFR levels in myeloid cells resolves patient stratification gaps and improves treatment efficacy.

Analyzing specific fetal membrane cells in maternal blood resolves prediction reliability gaps by enabling early clinical intervention.

Antibody-based fecal peptide detection replaces subjective interviews, resolving reliability gaps in celiac diet monitoring.

A multi-component biomarker panel detects acute kidney injury through segmented tubular and glomerular markers.

Measuring urinary apolipoprotein A1 concentration identifies diabetic patients at high or low risk of progressing to nephropathy.

A diagnostic kit detects urokinase-type plasminogen, matrix metalloproteinase 9, and beta-2-microglobulin levels in blood serum samples.

Concentrating mycobacteria from cerebrospinal fluid improves sensitivity while reducing turnaround time.

A biomarker composition measures amyloid beta 40, tau, and neuron-specific enolase levels in blood serum to detect degenerative brain diseases.

Tumoroids from biopsies measure size changes to predict platinum resistance, resolving heterogeneity limits.

Measuring RIP1 expression levels predicts metastatic potential in lung cancer patients after radiotherapy treatment.

Segmenting detection into rod-like and twisted seed systems resolves the contradiction between quantification precision and discriminatory information loss.

Measuring leukocyte and cytokine concentrations in rumen fluid identifies unsuitable dietary profiles, resolving insufficient prediction of balance alterations.

Metabolic biomarkers detected via mass spectrometry diagnose peripheral artery disease and differentiate clinical stages.

Immunoassay quantification of D-dimer thresholds replaces invasive synovial fluid sampling, reducing patient risk while maintaining diagnostic accuracy.

Measuring proADM fragments via sandwich immunoassays enables early shock identification before severe blood pressure decline, preventing organ dysfunction.

Assessing pre-treatment immune cell densities in tumor biopsies to predict patient response to cell therapy products despite limited biomarker availability.

Spectroscopic analysis of sputum biochemical markers identifies chronic obstructive pulmonary disease progression without invasive lung biopsies.

A competitive immunoassay test system uses immobilized pyrogen binding domains and labeled, displaceable ligands to detect pathogens through color reactions.

Pooling high-response basophils from multiple donors reduces intra-individual variability and improves diagnostic accuracy for chronic spontaneous urticaria.

Segmenting markers into activation and inflammation groups improves detection reliability while reducing device complexity and measurement time.

A multiplex flow cytometry bead assay detects heparin-induced thrombocytopenia antibodies using fluorophore-labeled secondary reagents.

GDF-15 biomarker analysis identifies patient susceptibility to cardiac interventions and predicts mortality risks.

A microsphere-based assay system quantifies IgG subclasses using detectably-labeled antibodies for precise clinical diagnostics.

Measuring CEACAM1 levels in blood provides high sensitivity and specificity to resolve diagnostic accuracy limitations in early bile duct carcinoma detection.

Direct staining of NK cell microparticles with specific markers avoids centrifugation losses, enabling accurate immune response monitoring.

A lateral flow immunoassay device detects and quantifies functional C1-INH in plasma samples using specific conjugate pad zones.

High-energy diets on LDLr-/- mice induce progressive renal damage, resolving inconsistent microalbuminuria found in conventional models.

Cell-free DNA analysis determines a blood tumor mutational burden score to guide immune checkpoint inhibitor selection without invasive tissue biopsy.

Blood-based ELISA assay detects MAZI autoantibodies to identify atherosclerosis, replacing costly CT angiography and eliminating radiation exposure.

Composite biomarker score quantifies individual cancer risk, reducing false positives and unnecessary radiation exposure.

Quantifying phosphoethanolamine via CE-TOFMS replaces subjective clinical impressions with precise biochemical measurement.

Specific cerebrospinal fluid biomarkers identify intrathecal inflammation to replace invasive brain biopsies while maintaining diagnostic accuracy.

A PK/PD model predicts haemoglobin concentration to optimize erythropoiesis stimulating agent dosing.

Hemin modifies urinary L-FABP chemical state to boost detection sensitivity, resolving inconsistent blood marker reliability in sepsis prognosis.

A diagnostic kit measures CD32 expression and granulocyte-to-lymphocyte ratios to identify Still's disease markers.

Measuring threonine phosphorylation in E2F4 protein identifies Alzheimer's disease risk through specific biomarker analysis.

Monoclonal antibodies detect alpha 1-antitrypsin isoforms in serum, resolving low sensitivity of CA125 biomarkers for reliable endometriosis diagnosis.

OSTERIX protein levels detect gastrointestinal tumors, resolving low sensitivity of conventional markers.